Publication Name	World Journal of Gastroenterology
Manuscript ID	40142
Country	Poland

Received	2018-06-06 00:55
Peer-Review Started	2018-06-06 09:10
First Decision by Editorial Office Director	2018-07-11 15:25
Return for Revision	2018-07-12 08:51
Revised	2018-08-14 21:31
Publication Fee Transferred
Second Decision by Editor	2018-08-20 08:12
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2018-08-24 09:24
Articles in Press	2018-08-24 09:24
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-17 01:06
Publish the Manuscript Online	2018-09-20 02:33

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Biosimilars in paediatric inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Joanna Sieczkowska-Golub, Dorota Jarzebicka, Grzegorz Oracz and Jaroslaw Kierkus
ORCID	Author(s) ORCID Number Joanna Sieczkowska-Golub http://orcid.org/0000-0003-1381-0742 Dorota Jarzebicka http://orcid.org/0000-0002-3977-7541 Grzegorz Oracz http://orcid.org/0000-0003-1938-7519 Jaroslaw Kierkus http://orcid.org/0000-0003-2272-1581
Funding Agency and Grant Number
Corresponding Author	Jaroslaw Kierkus, MD, PhD, Full Professor, The Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, The Children’s Memorial Health Institute, Aleja Dzieci Polskich 20, Warsaw 04-730, Poland. j.kierkus@med-net.pl
Key Words	Ulcerative colitis; Crohn’s disease; Biological treatment; Infliximab; Paediatric inflammatory bowel disease; Biosimilars
Core Tip	Data on the use of biosimilars among paediatric patients are limited. Nevertheless, several original papers support adult findings that biosimilars are as effective and safe as the reference infliximab in this population.
Publish Date	2018-09-20 02:33
Citation	Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027
URL	http://www.wjgnet.com/1007-9327/full/v24/i35/4021.htm
DOI	http://dx.doi.org/10.3748/wjg.v24.i35.4021

Full Article (PDF)	WJG-24-4021.pdf
Manuscript File	40142-Review.docx
Answering Reviewers	40142-Answering reviewers.pdf
Audio Core Tip	40142-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	40142-Conflict-of-interest statement.pdf
Copyright License Agreement	40142-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	40142-Language certificate.pdf
Peer-review Report	40142-Peer-review(s).pdf
Scientific Misconduct Check	40142-Scientific misconduct check.pdf
Scientific Editor Work List	40142-Scientific editor work list.pdf